AV5080 — Competitive Intelligence Brief

AV5080 (AV5080) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog antiviral. Area: Infectious Disease / Virology.

phase 3 Nucleoside analog antiviral Viral RNA-dependent RNA polymerase Infectious Disease / Virology Small molecule

Target snapshot

AV5080 (AV5080) — Viriom. AV5080 is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase, blocking replication of RNA viruses.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AV5080 TARGET	AV5080	Viriom	phase 3	Nucleoside analog antiviral	Viral RNA-dependent RNA polymerase
pegylated interferon alpha 2a, ribavirin	pegylated interferon alpha 2a, ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase
Infergen and ribavirin	Infergen and ribavirin	Kadmon Corporation, LLC	marketed	Interferon alpha and nucleoside analog combination	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase
interferon α 2b + ribavirin	interferon α 2b + ribavirin	The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)	marketed	Antiviral combination therapy	Interferon-α receptor; viral RNA-dependent RNA polymerase
E: Peg-interferon alpha-2a & Ribavirin	E: Peg-interferon alpha-2a & Ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor; viral RNA-dependent RNA polymerase
Peginterferon alfa-2a 40KD and Ribavirin	Peginterferon alfa-2a 40KD and Ribavirin	NORDynamIC Study Group	marketed	Interferon alpha with nucleoside analog	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase
standard treatment COVID-19 + Triazavirin	standard treatment COVID-19 + Triazavirin	Ain Shams University	marketed	Nucleoside analog antiviral	Viral RNA-dependent RNA polymerase (RdRp)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside analog antiviral class)

1. Merck Sharp & Dohme LLC · 3 drugs in this class
2. Hoffmann-La Roche · 2 drugs in this class
3. Göteborg University · 2 drugs in this class
4. Estetra · 1 drug in this class
5. Padagis LLC · 1 drug in this class
6. MinaPharm Pharmaceuticals · 1 drug in this class
7. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
8. NYU Langone Health · 1 drug in this class
9. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
10. Ain Shams University · 1 drug in this class